KUALA LUMPUR, Nov 18 (Bernama) -- SELLAS Life Sciences Group Inc (SELLAS), a late-stage clinical biopharmaceutical company, has announced positive topline results from the pivotal randomised Phase 3 REGAL trial evaluating galinpepimut-S (GPS), an immunotherapeutic cancer vaccine, in patients with acute myeloid leukaemia (AML).
SELLAS Reports Positive Phase 3 Cancer Vaccine Trial Results
SELLAS Reports Positive Phase 3 Cancer Vaccine Tri

Key takeaways
SELLAS reported that its Phase 3 REGAL trial of the cancer vaccine galinpepimut‑S met the primary overall survival endpoint in AML patients, showing a 41% lower risk of death versus best available treatment.
- The trial involved AML patients in second or later remission who could not receive stem cell transplants.
- Median overall survival was 24.0 months with the vaccine versus 14.7 months with standard care.
- The vaccine was well tolerated, with mostly mild injection‑site reactions and no new safety signals.
Summarised automatically by AI from the original article by Bernama. AI can make mistakes, so check the original for details.
Story details
- Published
- Section
- news
- Format
- Article
- Original
- bernama.com ↗
Related reporting
3 stories on this topic from 2 sources, oldest first.
- Bernama SELLAS Reports Positive Phase 3 Cancer Vaccine Trial Results (this story)